Alnylam Pharmaceuticals ALNY Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.71B+67.5% | $1.66B+71.2% | $1.49B+35.4% | $1.12B+14.9% | $1.02B+49.3% | ||
| $1.3B-19.1% | $1.25B-27.3% | $1.23B-26.2% | $1.74B+5.9% | $1.61B-4.3% | ||
| $1.64M-36.8% | —— | $2.55M-1.0% | $2.18M-19.4% | $2.6M-8.6% | ||
| $883.96M+111% | $777.57M+91.8% | $964.77M+173% | $567.11M+83.2% | $418.04M+30.1% | ||
| $84.03M+28.1% | $82.72M+5.4% | $75.38M-0.8% | $71.69M-14.6% | $65.58M-30.2% | ||
| $11.69M-50.0% | $14.18M-40.8% | $22.25M-0.5% | $22.87M-12.1% | $23.4M-7.9% | ||
| $65.46M+21.2% | $65.12M+0.2% | $35.5M-49.2% | $43.78M-34.2% | $53.99M-29.0% | ||
| $38.98M+18.3% | $32.34M+22.3% | $38.85M+68.0% | $33.75M+21.2% | $32.96M+32.8% | ||
| $242.1M+58.8% | $281.89M+141% | $188.04M+29.4% | $147.31M-4.8% | $152.42M-24.5% | ||
| $4.22B+29.1% | $4.05B+22.9% | $3.95B+17.8% | $3.64B+14.8% | $3.27B+9.4% | ||
| $518.26M+3.9% | $513.15M+2.1% | $501.75M-1.0% | $499.79M-3.4% | $498.68M-4.7% | ||
| $189.3M-4.0% | $194.92M+2.0% | $191.39M-2.6% | $192.4M-3.0% | $197.23M+0.9% | ||
| $63.55M-13.9% | $59.46M-9.0% | $55.84M-28.1% | $57.17M-20.5% | $73.82M+9.4% | ||
| $5.13B+21.7% | $4.97B+17.1% | $4.85B+15.4% | $4.57B+13.9% | $4.21B+10.2% | ||
| $946.49M+34.4% | $1.08B+36.1% | $1.15B+21.9% | $918.97M+13.6% | $704.17M+0.8% | ||
| $3.21M-88.6% | $4.85M-91.3% | $2.54M-96.4% | $15.08M-78.1% | $28.16M-63.4% | ||
| $45.66M-0.8% | $45.52M+8.7% | $44.76M+6.2% | $46.1M+10.7% | $46.01M+10.4% | ||
| $1.35B+25.5% | $1.47B+23.6% | $1.56B+27.4% | $1.3B+23.3% | $1.08B+14.2% | ||
| $218.03M-5.2% | $225.09M-1.9% | $223.42M-5.3% | $224.45M-6.2% | $230.06M-3.3% | ||
| $7.61M+29.6% | $7.59M+52.8% | $9.77M-97.3% | $10.93M-96.9% | $5.87M-98.2% | ||
| $4.05B-1.1% | $4.18B+0.1% | $4.62B+10.7% | $4.32B+7.5% | $4.1B+1.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| 250M0.0% | 250M+19,235% | 250M0.0% | 250M0.0% | 250M0.0% | ||
| $7.6B+1.3% | $7.51B+1.7% | $7.41B+2.1% | $7.69B+8.0% | $7.5B+8.9% | ||
| -$6.5B+11.6% | -$6.7B+8.0% | -$7.16B+0.6% | -$7.41B-4.5% | -$7.35B-3.8% | ||
| -$24.89M+33.6% | -$20.1M+41.8% | -$21.78M+12.3% | -$29.95M+13.5% | -$37.52M-39.0% | ||
| $1.08B+152% | $789.18M+1,076% | $233.89M+623% | $250.59M+8,271% | $426.14M+294% | ||
| $5.13B+21.7% | $4.97B+17.1% | $4.85B+15.4% | $4.57B+13.9% | $4.21B+10.2% | ||
| $1.3B-19.1% | $1.25B-27.3% | $1.23B-26.2% | $1.74B+5.9% | $1.61B-4.3% | ||
| $63.55M-13.9% | $59.46M-9.0% | $55.84M-28.1% | $57.17M-20.5% | $73.82M+9.4% | ||
| $189.3M-4.0% | $194.92M+2.0% | $191.39M-2.6% | $192.4M-3.0% | $197.23M+0.9% | ||
| $116.96M+9.1% | $125.98M+7.8% | $98.56M— | $104.36M— | $107.22M— | ||
| $189.3M-4.0% | $194.92M+2.0% | $191.39M-2.6% | $192.4M-3.0% | $197.23M+0.9% | ||
| $63.55M-13.9% | $59.46M-9.0% | $55.84M-28.1% | $57.17M-20.5% | $73.82M+9.4% | ||
| $189.3M-4.0% | $194.92M+2.0% | $191.39M-2.6% | $192.4M-3.0% | $197.23M+0.9% | ||
| $63.55M-13.9% | $59.46M-9.0% | $55.84M-28.1% | $57.17M-20.5% | $73.82M+9.4% | ||
| —— | $0— | —— | —— | —— | ||
| $946.49M+34.4% | $1.08B+36.1% | $1.15B+21.9% | $918.97M+13.6% | $704.17M+0.8% | ||
| $946.49M+34.4% | $1.08B+36.1% | $1.15B+21.9% | $918.97M+13.6% | $704.17M+0.8% | ||
| $227.49M— | $220.07M+94.7% | —— | —— | —— | ||
| $1.01B-1.6% | $1.01B-1.6% | $1.04B+1.6% | $1.03B+0.4% | $1.03B+0.4% | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| 133.4M+2.4% | 132.4M+2.4% | 131.8M+2.3% | 131M+2.3% | 130.3M+3.0% | ||
| 5M0.0% | 5M0.0% | 5M0.0% | 5M0.0% | 5M0.0% | ||
| 0— | 0— | 0— | 0— | 0— | ||
| 0— | 0— | 0— | 0— | 0— | ||
| $7.6B+1.3% | $7.51B+1.7% | $7.41B+2.1% | $7.69B+8.0% | $7.5B+8.9% | ||
| $1.33M+2.4% | $1.32M+2.4% | $1.32M+2.2% | $1.31M+2.3% | $1.3M+3.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| $250M0.0% | $250M0.0% | $250M0.0% | $250M0.0% | $250M0.0% | ||
| $133.44M+2.4% | $132.38M+2.4% | $131.79M+2.3% | $130.98M+2.3% | $130.31M+3.0% | ||
| $133.44M+2.4% | $132.38M+2.4% | $131.79M+2.3% | $130.98M+2.3% | $130.31M+3.0% | ||
| $1.01B-1.6% | $1.01B-1.6% | $1.04B+1.6% | $1.03B+0.4% | $1.03B+0.4% | ||
| $1.4M— | $88K— | —— | —— | —— | ||
| $1.11M— | $3.45M— | —— | —— | —— | ||
| $1.6B— | $1.27B— | —— | —— | —— | ||
| $1.6B— | $1.27B— | —— | —— | —— | ||
| $116.12M+5.2% | $111.64M-3.2% | $96.61M-16.3% | $100.4M-16.6% | $110.35M-12.6% | ||
| $11.69M-50.0% | $14.18M-40.8% | $22.25M-0.5% | $22.87M-12.1% | $23.4M-7.9% | ||
| —— | $0— | —— | —— | —— | ||
| 40.0% | —— | 40.0% | 40.0% | 40.0% | ||
| 20.0% | —— | 2+100% | 2+100% | 2+100% | ||
| 60.0% | —— | 6— | 6— | 6— | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| $5M0.0% | $5M0.0% | $5M0.0% | $5M0.0% | $5M0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $22.17M-67.7% | $22.17M-67.7% | $51.31M-25.2% | $68.59M+38.9% | $68.59M+38.9% | ||
| $1.47B— | $1.47B+10.2% | —— | —— | —— | ||
| $477.04M— | $425.65M+17.6% | $559.42M— | $473.94M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Alnylam Pharmaceuticals's total assets?
- Alnylam Pharmaceuticals (ALNY) holds $5.1B in total assets, up 21.7% year over year.
- How much debt does Alnylam Pharmaceuticals have?
- Alnylam Pharmaceuticals carries $263.7M in total debt against $1.1B of shareholders' equity, a debt-to-equity ratio of 0.25.
- How much cash does Alnylam Pharmaceuticals have?
- Alnylam Pharmaceuticals holds $1.7B in cash and equivalents.
- Can Alnylam Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.13 — current assets exceed current liabilities.
- Where does Alnylam Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
